ODTX
Odyssey Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
26.39
▲ 1.72 (6.97%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.09
Prev close
24.67
Day high
26.49
Day low
24.55
Volume
181.27K
Market cap
$1.27B
P/E (TTM)
—
52W range
15.10 – 26.49
Day trading desk
Gap from prior close
+1.70%
Prior close 24.67
VWAP
25.72
+2.61% from price
Relative volume
0.60×
Normal
Session range
7.90%
24.55 – 26.49
Position in range
95%
Near session high
ATR (14D)
1.90
7.20% of price
Prior day high
24.77
PDH
Prior day low
23.07
PDL
Bid / ask spread
—
Quote not published
Session volume
169.02K
Avg 280.21K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+27.30%
+28.7%
1M
+49.35%
+45.6%
3M
+48.76%
+45.7%
6M
—
-11.1%
YTD
+60.72%
+48.4%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ODTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+12.79M
Net buying
Buy transactions
14
12.79M shares
Sell transactions
1
1.78K shares
Net transactions
+15
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
2.91M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 11, 26 | LEIDEN JEFFREY M Director |
— | 31.66K | — | Indirect |
| May 11, 26 | SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 555.55K | $10.00M | Indirect |
| May 11, 26 | SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 1.78K | $32.04K | Indirect |
| May 11, 26 | SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
— | 3.24M | — | Indirect |
| May 11, 26 | TPG GP A, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.39M | $25.00M | Indirect |
| May 11, 26 | TPG GP A, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
— | 1.88M | — | Indirect |
| May 11, 26 | CHU SHELLEY Director |
BUY | 11.11K | $200.00K | Direct |
| May 11, 26 | LI NAN LN Director |
BUY | 1.11M | $20.00M | Indirect |
| May 11, 26 | LI NAN LN Director |
— | 1.71M | — | Indirect |
| May 11, 26 | OPIPARI ANTHONY W M.D., PH.D. Officer |
— | 7.51K | — | Direct |
| May 11, 26 | GLICK GARY D. PH.D. Chief Executive Officer |
— | 27.39K | — | Direct |
| May 8, 26 | LEIDEN JEFFREY M Director |
BUY | 5.00K | $82.10K | Direct |
| May 8, 26 | HAAS JASON Chief Financial Officer |
BUY | 1.00K | $16.42K | Direct |
| May 8, 26 | DIMENSION CAPITAL II, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.11M | $20.00M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHU SHELLEY |
Director | 11.11K | Purchase |
DIMENSION CAPITAL II, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
GLICK GARY D. PH.D. |
Chief Executive Officer | 415.97K | Conversion of Exercise of derivative security |
HAAS JASON |
Chief Financial Officer | 62.91K | Purchase |
LEIDEN JEFFREY M |
Director | — | Conversion of Exercise of derivative security |
LI NAN LN |
Director | — | Purchase |
OPIPARI ANTHONY W M.D., PH.D. |
Officer | 7.50K | Conversion of Exercise of derivative security |
SR ONE CAPITAL MANAGEMENT, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
TPG GP A, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$1.27B
Enterprise value$978.82M
Revenue (TTM)$99.00K
Gross profit$-120.62M
EBITDA$-150.27M
Net income$-160.03M
EPS (TTM)$-3.34
Free cash flow—
Total cash$310.58M
Total debt$24.82M
Book value / share$8.80
Shares outstanding48.06M
Float19.97M
Short % of float5.40%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.05
PEG ratio—
Price / sales—
Price / book3.00
EV / revenue9,887.05
EV / EBITDA-6.51
Gross margin0.00%
Operating margin-156392.92%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity5.89
Current ratio11.36
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.98M | $4.47M | $1.04M | $0 | -33.5% |
| Operating revenue | $2.98M | $4.47M | $1.04M | $0 | -33.5% |
| Research & development | $126.62M | $112.58M | $112.28M | $101.75M | +12.5% |
| Selling, general & admin | $37.52M | $27.12M | $22.20M | $21.02M | +38.4% |
| Total operating expense | $164.13M | $139.69M | $134.48M | $122.78M | +17.5% |
| Operating income | -$161.16M | -$135.22M | -$133.44M | -$122.78M | -19.2% |
| Net interest income | $6.33M | $8.47M | $8.46M | $3.63M | -25.3% |
| Pre-tax income | -$149.57M | -$128.85M | -$125.49M | -$124.32M | -16.1% |
| Tax provision | -$927.00K | $469.00K | $447.00K | $347.00K | -297.7% |
| Net income | -$148.65M | -$129.32M | -$125.94M | -$124.67M | -14.9% |
| Net income to common | -$148.65M | -$130.40M | -$130.92M | -$124.67M | -14.0% |
| Basic EPS | -5.39 | -4.73 | -1.32 | -4.52 | -13.9% |
| Diluted EPS | -5.39 | -4.73 | -1.32 | -4.52 | -13.9% |
| EBIT | -$149.56M | -$128.83M | -$125.16M | -$124.03M | -16.1% |
| EBITDA | -$144.65M | -$123.64M | -$120.25M | -$121.26M | -17.0% |
| Basic shares | 27.56M | 27.56M | 99.23M | 27.56M | 0.0% |
| Diluted shares | 27.56M | 27.56M | 99.23M | 27.56M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $41.69M | $59.14M | $52.55M | $241.04M | -29.5% |
| Cash & short-term investments | $181.36M | $129.35M | $187.00M | $241.04M | +40.2% |
| Total current assets | $190.66M | $135.51M | $192.54M | $248.71M | +40.7% |
| Property, plant & equipment | $26.01M | $39.47M | $46.73M | $52.77M | -34.1% |
| Goodwill & intangibles | $14.59M | $13.92M | $14.46M | $14.06M | +4.8% |
| Total assets | $269.79M | $197.44M | $286.52M | $317.15M | +36.6% |
| Total current liabilities | $26.48M | $28.41M | $22.09M | $22.80M | -6.8% |
| Long-term debt | — | — | — | $4.76M | — |
| Total debt | $27.11M | $31.01M | $34.38M | $42.49M | -12.6% |
| Total liabilities | $758.07M | $579.96M | $549.23M | $461.77M | +30.7% |
| Retained earnings | -$568.14M | -$419.49M | -$289.09M | -$158.17M | -35.4% |
| Shareholder equity | -$488.28M | -$382.53M | -$262.71M | -$144.62M | -27.6% |
| Working capital | $164.18M | $107.09M | $170.45M | $225.91M | +53.3% |
| Net tangible assets | -$502.87M | -$396.44M | -$277.17M | -$158.68M | -26.8% |
| Shares issued | 47.17M | 47.17M | 47.17M | 47.17M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$148.65M | -$129.32M | -$125.94M | -$124.67M | -14.9% |
| Depreciation & amortisation | $4.91M | $5.19M | $4.91M | $2.76M | -5.4% |
| Stock-based compensation | $14.32M | $8.69M | $6.26M | $5.52M | +64.9% |
| Change in working capital | -$4.73M | -$3.31M | $896.00K | -$544.00K | -43.0% |
| Operating cash flow | -$129.47M | -$117.47M | -$112.73M | -$99.84M | -10.2% |
| Capital expenditure | -$1.23M | -$764.00K | -$5.06M | -$13.03M | -61.3% |
| Investing cash flow | -$103.94M | $96.78M | -$165.02M | -$13.03M | -207.4% |
| Financing cash flow | $215.65M | $26.98M | $92.08M | $182.72M | +699.3% |
| Free cash flow | -$130.70M | -$118.23M | -$117.78M | -$112.87M | -10.5% |
| End cash position | $44.90M | $62.35M | $56.00M | $241.67M | -28.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $959.00K | $1.92M | $1.75M | — |
| Operating revenue | $0 | $0 | $959.00K | $1.92M | $1.75M | — |
| Research & development | $36.23M | $32.32M | $30.23M | $38.77M | $31.48M | +12.1% |
| Selling, general & admin | $10.51M | $7.35M | $13.22M | $7.95M | $7.40M | +43.0% |
| Total operating expense | $46.74M | $39.67M | $43.45M | $46.73M | $38.88M | +17.8% |
| Operating income | -$46.74M | -$39.67M | -$42.49M | -$44.81M | -$37.12M | -17.8% |
| Net interest income | $2.81M | $1.70M | $870.00K | $1.15M | $1.77M | +65.6% |
| Pre-tax income | -$52.80M | -$38.20M | -$41.20M | -$38.30M | -$35.88M | -38.2% |
| Tax provision | -$8.00K | $63.00K | $30.00K | $140.00K | $47.00K | -112.7% |
| Net income | -$52.79M | -$38.26M | -$41.23M | -$38.44M | -$35.93M | -38.0% |
| Net income to common | -$52.79M | -$38.26M | -$41.23M | -$38.44M | -$36.84M | -38.0% |
| Basic EPS | -1.74 | -0.81 | -1.50 | -1.39 | — | -114.5% |
| Diluted EPS | -1.74 | -0.81 | -1.50 | -1.39 | — | -114.5% |
| EBIT | -$52.78M | -$38.19M | -$41.20M | -$38.29M | -$35.88M | -38.2% |
| EBITDA | -$51.73M | -$37.02M | -$39.94M | -$36.99M | -$34.59M | -39.8% |
| Basic shares | 30.28M | 47.17M | 27.56M | 27.56M | — | -35.8% |
| Diluted shares | 30.28M | 47.17M | 27.56M | 27.56M | — | -35.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $82.03M | $35.72M | $59.14M | +129.7% |
| Cash & short-term investments | $310.57M | $175.75M | $129.35M | +76.7% |
| Total current assets | $321.46M | $185.10M | $135.51M | +73.7% |
| Property, plant & equipment | $21.92M | $24.48M | $39.47M | -10.5% |
| Goodwill & intangibles | $14.19M | $14.23M | $13.92M | -0.3% |
| Total assets | $483.85M | $229.07M | $197.44M | +111.2% |
| Total current liabilities | $28.30M | $22.21M | $28.41M | +27.4% |
| Total debt | $24.82M | $26.13M | $31.01M | -5.0% |
| Total liabilities | $62.63M | $752.76M | $579.96M | -91.7% |
| Retained earnings | -$659.19M | -$606.40M | -$419.49M | -8.7% |
| Shareholder equity | $421.22M | -$523.69M | -$382.53M | +180.4% |
| Working capital | $293.17M | $162.89M | $107.09M | +80.0% |
| Net tangible assets | $407.04M | -$537.93M | -$396.44M | +175.7% |
| Shares issued | 48.03M | 47.17M | 47.17M | +1.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$52.79M | -$38.26M | -$41.23M | -$38.44M | -$35.93M | -38.0% |
| Depreciation & amortisation | $1.04M | $1.17M | $1.27M | $1.30M | $1.29M | -10.9% |
| Stock-based compensation | $5.67M | $2.59M | $3.70M | $2.99M | $2.66M | +119.2% |
| Change in working capital | $1.17M | -$7.19M | $2.42M | -$5.28M | -$2.54M | +116.3% |
| Operating cash flow | -$34.51M | -$41.03M | -$34.26M | -$38.62M | -$34.29M | +15.9% |
| Capital expenditure | -$186.00K | -$148.00K | -$29.00K | -$927.00K | -$265.00K | -25.7% |
| Investing cash flow | -$211.44M | $34.80M | $23.30M | $34.13M | $47.14M | -707.6% |
| Financing cash flow | $292.16M | $484.00K | $118.72M | $200.00K | $6.82M | +60,263.6% |
| Free cash flow | -$34.69M | -$41.18M | -$34.29M | -$39.55M | -$34.55M | +15.8% |
| End cash position | $85.48M | $39.17M | $166.21M | $58.12M | $62.35M | +118.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.85 | -1.27 | -49.1% |
| Mar 2026 | -1.28 | -6.75 | -427.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.93 | 3 | $0 | — |
| Next quarter | -1.01 | 3 | $0 | — |
| Current year | -4.26 | 3 | $0 | — |
| Next year | -4.36 | 3 | $0 | 0.0% |
Analyst targets & ownership
Mean target$33.00
High target$40.00
Low target$29.00
Implied upside25.05%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy1 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders6.07%
Held by institutions82.91%
Institutions holding60
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
22.37
+17.99% from price
SMA 20
20.91
+26.20% from price
SMA 50
18.93
+39.38% from price
SMA 100
—
—
SMA 200
—
—
EMA 12
22.48
+17.40% from price
EMA 26
20.86
+26.50% from price
EMA 50
19.61
+34.55% from price
RSI (14)
75.2
Overbought
MACD (12,26,9)
1.62
Hist 0.49
ATR (14)
1.90
7.20% of price
Realised vol 30D
67.4%
Annualised
Bollinger upper
25.29
20, 2σ
Bollinger lower
16.53
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.30
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
67.4%
Annualised
Market vol 1Y
13.2%
SPY, annualised
Max drawdown 1Y
-18.4%
Peak to trough
Max drawdown 5Y
-18.4%
Peak to trough
ATR 14
1.90
7.20% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
2.27M
Prior 1.80M
Change vs prior
+26.4%
Shorts adding
% of float
5.40%
Normal
% of shares out
4.73%
Against total outstanding
Days to cover
8.1
Crowded exit
Float
19.97M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jun 18, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jun 2, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Jun 2, 26 | TD Cowen | INITIATED | — | Buy |
| Jun 2, 26 | Wedbush | INITIATED | — | Outperform |
| Jun 2, 26 | JP Morgan | INITIATED | — | Overweight |
| Jun 2, 26 | Oppenheimer | INITIATED | — | Outperform |
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-23
Periodic Financial Reports
10-Q · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-05-11
Offering Registrations
S-1MEF · 2026-05-07
Trading Registrations
8-A12B · 2026-05-05
Offering Registrations
S-1/A · 2026-05-04
Headlines
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention
Simply Wall St. · 13d ago
Evotec and Odyssey collaborate on AI-enabled R&D
Pharmaceutical Technology · 16d ago
Odyssey Therapeutics: Q2 Earnings Snapshot
Associated Press · 17d ago
Evotec, Odyssey Therapeutics Partner to Develop Autoimmune, Inflammatory Disease Treatments
MT Newswires · 17d ago
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
PR Newswire · 17d ago
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 19d ago
Kardigan rises in Nasdaq debut after upsized $400 million IPO
Reuters · 66d ago
Odyssey Therapeutics: Q1 Earnings Snapshot
Associated Press · 67d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.